drugset
drugset / Trial / NCT05100160

Gabapentin for the Reduction of Opiate Use Following Pulmonary Resection (GROUP Trial)

NCT05100160 ↗

Phase 3 Withdrawn M.D. Anderson Cancer Center
Non-randomizedSingle-groupOpen-labelSupportive care

Summary

The aim of this study is to determine if the reduction in narcotic requirement following pulmonary resection with gabapentin is clinically significant when compared to the effect seen with placebo. We have defined clinically meaningful as a reduction by 30 Morphine equivalent doses (MED)

Timeline

Start
2021-09-15
Primary completion
2023-01-03
Completion
2023-01-03

Outcome

Outcome not reported

Stopped (Enrollment): “0 patient accrual”

Drugs

EvaluationDrugModalityDoseRoute
Subject Gabapentin Unknown — Oral

Indications

lung disorder